In the ongoing search for new methods to address the HIV epidemic, the development of lenacapavir for HIV prevention is a major step forward. Findings from research studies has shown that twice-yearly injection of long-acting lenacapavir provides protection against HIV infection. This discovery offers great promise in advancing our progress towards ending AIDS as a public health threat.

In this special lecture hosted by ICAP on October 14, 2025 at the Columbia Mailman School of Public Health, Moupali Das, MD, MPH, vice president, Clinical Development, HIV Prevention and Virology Pediatrics at Gilead Sciences, provided an update on research findings on lenacapavir for HIV prevention. Her talk covers the status of the PURPOSE 1-5 studies, reviews ongoing implementation science studies, and looks at the pipeline for pre-exposure prophylaxis (PrEP) at a pivotal moment for the global HIV response.

View the Recording >>> .